We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab (PIRG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05235737
Recruitment Status : Not yet recruiting
First Posted : February 11, 2022
Last Update Posted : March 10, 2022
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Information provided by (Responsible Party):
Wojciech Kaspera, Medical University of Silesia

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : June 1, 2025
Estimated Study Completion Date : May 30, 2026